Daxor Corporation - SIC # 8040 -

Ticker Exchange SIC # Website Latest Ticker
DXR Nasdaq 8040 www.daxor.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Daxor Corporation

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum - Dec 18th, 2024 1:00 pm
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 - Oct 9th, 2024 12:00 pm
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Oct 8th, 2024 12:00 pm
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device - Sep 27th, 2024 9:00 pm
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 - Sep 19th, 2024 12:00 pm
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management - Sep 12th, 2024 12:00 pm
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee - Sep 5th, 2024 12:00 pm
Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care - Sep 4th, 2024 12:30 pm
Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter - Sep 3rd, 2024 8:05 pm
Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 4:15 pm
Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network - Aug 29th, 2024 12:00 pm
Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume Analyzer - Aug 6th, 2024 12:00 pm
Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum Nationwide - Aug 5th, 2024 12:00 pm
Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume Analyzer - Jul 24th, 2024 12:00 pm
Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide - Jul 11th, 2024 12:00 pm
Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting - Jun 18th, 2024 12:00 pm
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer - Jun 5th, 2024 12:00 pm
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion - Apr 16th, 2024 12:00 pm
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™) - Apr 15th, 2024 12:00 pm
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital - Apr 10th, 2024 12:00 pm